IRVINE, Calif.--(BUSINESS WIRE)-- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation ...
* AXONICS MODULATION TECHNOLOGIES - FDA REVIEW OF LABELING EXPANSION EXPECTED TO COMPLETE IN EARLY Q4 Source text for Eikon: Further company coverage: ...
IRVINE, Calif.--(BUSINESS WIRE)-- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation ...
In November, the Food and Drug Administration (FDA) approved r-SNM, the first rechargeable sacral nerve stimulator cleared for full-body MRI scans, and sales results from the initial launch were ...
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics F15™ ...